全文获取类型
收费全文 | 407篇 |
免费 | 52篇 |
国内免费 | 4篇 |
专业分类
妇产科学 | 2篇 |
基础医学 | 32篇 |
临床医学 | 27篇 |
内科学 | 226篇 |
神经病学 | 1篇 |
特种医学 | 11篇 |
外科学 | 7篇 |
综合类 | 44篇 |
预防医学 | 8篇 |
药学 | 70篇 |
1篇 | |
中国医学 | 33篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 1篇 |
2023年 | 13篇 |
2022年 | 20篇 |
2021年 | 16篇 |
2020年 | 31篇 |
2019年 | 26篇 |
2018年 | 13篇 |
2017年 | 17篇 |
2016年 | 46篇 |
2015年 | 31篇 |
2014年 | 56篇 |
2013年 | 47篇 |
2012年 | 42篇 |
2011年 | 36篇 |
2010年 | 11篇 |
2009年 | 19篇 |
2008年 | 17篇 |
2007年 | 12篇 |
2006年 | 4篇 |
2005年 | 4篇 |
2003年 | 1篇 |
排序方式: 共有463条查询结果,搜索用时 0 毫秒
51.
52.
Suzuki F Toyoda J Katano Y Sata M Moriyama M Imazeki F Kage M Seriu T Omata M Kumada H 《Journal of gastroenterology and hepatology》2008,23(9):1320-1326
Background and Aim: Entecavir is a potent inhibitor of both wild-type and lamivudine-resistant hepatitis B virus (HBV) with proven clinical efficacy. We conducted a randomized, double-blind, multicenter study in Japan (ETV-052) evaluating the efficacy and safety of two doses of entecavir in adult patients with lamivudine-refractory chronic hepatitis B infection.
Methods: Eighty-four patients with chronic hepatitis B who were refractory to lamivudine therapy were switched from lamivudine to daily oral doses of 0.5 mg entecavir (41 patients) or 1 mg entecavir (43 patients) for 52 weeks.
Results: The proportions of patients achieving the primary end-point (≥2 log10 reduction in HBV-DNA from baseline by polymerase chain reaction assay or undetectable HBV-DNA levels [<400 copies/mL] at week 48) were 90% and 93% for entecavir 0.5 mg and 1 mg, respectively, with 33% of patients in each dosing group achieving <400 copies/mL. The mean reduction in HBV-DNA from baseline was 3.58 and 3.75 log10 copies/mL for entecavir 0.5 mg and 1 mg, respectively. High proportions of patients achieved alanine aminotransferase normalization at week 48 (0.5 mg 86%, 1 mg 78%). Histological improvement was observed in most patients (0.5 mg 52%, 1 mg 60%). Virological breakthrough (increase in HBV-DNA of ≥1 log10 copies/mL from nadir) was observed in one patient but was not associated with selection of entecavir-associated resistance substitutions. Entecavir was well tolerated, with no patients discontinuing study drug due to adverse events.
Conclusions: These findings indicate that entecavir is safe and effective for the treatment of Japanese adults with lamivudine-refractory chronic hepatitis B. 相似文献
Methods: Eighty-four patients with chronic hepatitis B who were refractory to lamivudine therapy were switched from lamivudine to daily oral doses of 0.5 mg entecavir (41 patients) or 1 mg entecavir (43 patients) for 52 weeks.
Results: The proportions of patients achieving the primary end-point (≥2 log
Conclusions: These findings indicate that entecavir is safe and effective for the treatment of Japanese adults with lamivudine-refractory chronic hepatitis B. 相似文献
53.
Reappraisal of serum alpha‐foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment 下载免费PDF全文
54.
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study 下载免费PDF全文
55.
56.
57.
58.
59.
60.
《Expert opinion on biological therapy》2013,13(5):751-761
Chronic hepatitis B virus (HBV) infection affects > 350 million individuals worldwide. Chronic hepatitis B is associated with complications of end-stage liver disease, including cirrhosis and hepatocellular carcinoma. HBV replication is the best predictor of liver disease progression to cancer, and antiviral therapy may diminish or halt this unfavorable outcome. Six drugs have been approved for the treatment of chronic hepatitis B: interferon-α2b, pegylated interferon-α2a, lamivudine, adefovir, entecavir and telbivudine. Most agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy; therefore, new agents and treatment strategies are needed. Telbivudine is the latest approved anti-HBV agent; it is an orally administered nucleoside analog that selectively inhibits HBV replication. It has demonstrated potent activity against HBV in Phase III clinical studies, with good tolerance, lack of mitochondrial toxicity and no dose-limiting side effects. 相似文献